Voltage-gated K+ channels (KV) are involved in diverse physiological processes and offer important drug development opportunities for cancer and autoimmune diseases, as well as metabolic, neurological and cardiovascular disorders. Here, Wulff and colleagues discuss strategies to pharmacologically modulate KV channels and highlight recent progress in developing drugs that target specific KVsubfamilies.
- Heike Wulff
- Neil A. Castle
- Luis A. Pardo